Skip to content
Tablet Allopathic

Erdafixen 4 mg tablet

Generic: Erdafitinib

Company: Everest Pharmaceuticals Ltd.. Prices are as listed on BestinMeds; your pharmacy price may differ.

Strength4 mg
PackNot listed yet

Reviewed by: not listed yet. Source: not listed yet.

Last updated October 14, 2025.

Compare

Same generic, same strength

Sorted by price per tablet. Ask your pharmacist before you switch brands.

Erdafitinib 4 mg tablets

Prices as listed on BestinMeds.

1 brand listed
Erdafixen (this medicine)700.00 taka per tablet

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250
Medicine guide

About this medicine

What this medicine is for, how to take it, and what to watch for.

Read the full Erdafitinib guide

Indications

Erdafitinib is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) that has- Susceptible FGFR3 or FGFR2 genetic alterations and Progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

Dosage and administration

The recommended starting dose of Erdafitinib is 8 mg (two 4 mg tablets) orally once daily, with a dose increase to 9 mg (three 3 mg tablets) once daily based on serum phosphate (PO4) levels and tolerability at 14 to 21 days. Treatment should be continued until disease progression or unacceptable toxicity occurs. If a dose of Erdafitinib is missed, it can be taken as soon as possible on the same day. The regular daily dose schedule for Erdafitinib should be resumed the next day. Extra tablets should not be taken to make up for the missed dose.

Side effects

The most common adverse reactions including laboratory abnormalities (≥20%) are elevated phosphate, stomatitis, fatigue, elevated creatinine, diarrhea, dry mouth, nail disorder, elevated alanine aminotransferase, elevated alkaline phosphatase, decrease in sodium, decrease in appetite, decrease in albumin, dysgeusia, decrease in hemoglobin, dry skin, elevated aspartate aminotransferase, decrease in magnesium, dry eye, alopecia, palmar-plantar erythrodysesthesia syndrome, constipation, decrease in phosphate, abdominal pain, elevated calcium, nausea, and musculoskeletal pain.

Precautions and warnings

This information is not available. Ask your doctor or pharmacist.

Pregnancy and lactation

Ocular disorders: Erdafitinib can cause central serous retinopathy/retinal pigment epithelial detachment (CSR/RPED). Monthly ophthalmological examinations should be performed during the first four months of treatment, every 3 months afterwards, and at any time for visual symptoms. When CSR/RPED occurs, Erdafitinib should be withheld and permanently discontinued if it does not resolve within 4 weeks or if Grade 4 in severity. Hyperphosphatemia: Hyperphosphatemia should be monitored and managed with dose modifications when required. Embryo-fetal toxicity: Since it can cause fetal harms so patients of the potential risk to the fetus should be advised to use effective contraception.

Clinical details

BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250